Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: Amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 845, Issue 1, 2007, Pages 51-60

  Verbesselt, R ^a   Van Wijngaerden, E ^a   de Hoon, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chromatography; Drug monitoring; Protease inhibitors

Indexed keywords

BORATE MINERALS; CALIBRATION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; PH EFFECTS; ULTRAVIOLET DETECTORS;

BORATE BUFFERS; HIV PROTEASE INHIBITORS; HUMAN PLASMA; THERAPEUTIC DRUG MONITORING;

BIOMEDICAL ENGINEERING;

ABACAVIR; ACETIC ACID ETHYL ESTER; ACICLOVIR; ALPRAZOLAM; AMOXICILLIN; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATENOLOL; ATORVASTATIN; BORIC ACID; CETIRIZINE; DAPSONE; DICLOFENAC; DIDANOSINE; DILTIAZEM; DRUG METABOLITE; EFAVIRENZ; FENOFIBRATE; HEXANE; INDINAVIR; LOPERAMIDE; LOPINAVIR; LORAZEPAM; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG;

ACCURACY; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EXTRACTION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; PH; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; STANDARD; TEMPERATURE SENSITIVITY; ULTRAVIOLET SPECTROSCOPY;

CALIBRATION; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; FLUORESCENCE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; REPRODUCIBILITY OF RESULTS; RITONAVIR; SAQUINAVIR; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; ULTRAVIOLET RAYS;

EID: 33751501472     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.07.068     Document Type: Article

References (27)

1. Rezk N.L., Tidwell R.R., and Kashuba A.D.M. J. Chromatogr. B 805 (2004) 241
2. Droste J.A.H., Verweij-van Wissen C.P.W.G.M., and Burger D.M. Ther. Drug Monit. 25 (2003) 393
3. Keil K., Frerichs V.A., DiFrancesco R., and Morse G. Ther. Drug Monit. 25 3 (2003) 340
4. Donnerer J., Kronawetter M., Kapper A., Haas I., and Kessler H.H. Pharmacology 69 (2003) 197
5. Aarnoutse R.E., Verweij-van Wissen C.P.W.G.M., Underberg W.J.M., Kleinnijenhuis J., Hekster Y.A., and Burger D.M. J. Chromatogr. B 764 (2001) 363
6. Tribut O., Arvieux C., Michelet C., Chapplain J.M., Allain H., and Bentué-Ferrer D. Ther. Drug Monit. 24 (2002) 554
7. Titier K., Lagrange F., Péhourcq F., Edno-Mcheik L., Moore N., and Molimard M. Ther. Drug Monit. 24 (2002) 417
8. Justesen U.S., Pedersen C., and Klitgaard N.A. J. Chromatogr. B 783 (2003) 491
9. Turner M.L., Reed-Walker K., King J.R., and Acosta E.P. J. Chromatogr. B 784 (2003) 331
10. Sarasa-Nacenta M., Lopez-Pua Y., Mallolas J., Blanco J.L., Gatell J.M., and Carné X. J. Chromatogr. B 757 (2001) 325
11. Dailly E., Thomas L., Kergueris M.F., Jolliet P., and Bourin M. J. Chromatogr. B 758 (2001) 129
12. Dailly E., Raffi F., and Jolliet P. J. Chromatogr. B 813 (2004) 353
13. Tribut O., Verdier M.C., Arvieux C., Allain H., Michelet C., and Bentué-Ferrer D. Ther. Drug Monit. 27 3 (2005) 265
14. Cateau E., Tournier N., Dupuis A., Le Moal G., and Venisse N. J. Pharm. Biomed. Anal. 39 3-4 (2005) 791
15. Pélerin H., Compain S., Duval X., Gimenez F., Bénech H., and Mabondzo A. J. Chromatogr. B 819 (2005) 47
16. Poirier J.M., Robidou P., and Jaillon P. Ther. Drug Monit. 27 2 (2005) 186
17. Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., and Decosterd L.A. J. Chromatogr. B 810 (2004) 25
18. Dickinson L., Robinson L., Tjia J., Khoo S., and Back D. J. Chromatogr. B 829 (2005) 82
19. Pelerin H., Compain S., Duval X., Gimenez F., Benech H., and Mabondzo A. J. Chromatogr. B 819 (2005) 47
20. Crommentuyn K.M.L., Rosing H., Hillebrand M.J.X., Huitema A.D.R., and Beijnen J.H. J. Chromatogr. B 804 (2004) 359
21. Rouzes A., Berthoin K., Xuereb F., Djabarouti S., Pellegrin I., Pellegrin J.L., Coupet A.C., Augagneur S., Budzinski H., Saux M.C., and Breilh D. J. Chromatogr. B 813 (2004) 209
22. Frerichs V., DiFrancesco R., and Morse G.D. J. Chromatogr. B 787 (2003) 393
23. Rentsch K.M. J. Chromatogr. B 788 (2003) 339
24. Aarnoutse R.E., Schapiro J.M., Boucher C.A.B., Hekster Y.A., and Burger D.M. Drugs 63 8 (2003) 741
25. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelley J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., and Spector S. Eur. J. Drug Metab. Pharmacokinet. 16 (1991) 249
26. http://www.fda.gov/cvm. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary medicine (CVM), BP, May 2001.
27. S. Preston, P. Piliero, E. O'Mara, et al., Evaluation of the steady state interaction between atazanavir (ATV) and efavirenz (EFV) [abstract #443]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2002 Feb 24-28.